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Abstract
Background: Heterologous prime boost immunization with chimpanzee adenovirus 63 (ChAd63) and Modified vaccinia
Virus Ankara (MVA) vectored vaccines is a strategy recently shown to be capable of inducing strong cell mediated responses
against several antigens from the malaria parasite. ChAd63-MVA expressing the Plasmodium falciparum pre-erythrocytic
antigen ME-TRAP (multiple epitope string with thrombospondin-related adhesion protein) is a leading malaria vaccine
candidate, capable of inducing sterile protection in malaria naı̈ve adults following controlled human malaria infection
(CHMI).
Methodology: We conducted two Phase Ib dose escalation clinical trials assessing the safety and immunogenicity of
ChAd63-MVA ME-TRAP in 46 healthy malaria exposed adults in two African countries with similar malaria transmission
patterns.
Results: ChAd63-MVA ME-TRAP was shown to be safe and immunogenic, inducing high-level T cell responses (median
.1300 SFU/million PBMC).
Conclusions: ChAd63-MVA ME-TRAP is a safe and highly immunogenic vaccine regimen in adults with prior exposure to
malaria. Further clinical trials to assess safety and immunogenicity in children and infants and protective efficacy in the field
are now warranted.
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Introduction
Malaria caused by Plasmodium falciparum remains a leading cause
of childhood morbidity and mortality, predominantly in Africa, in
spite of the implementation of extensive control measures [1,2].
An effective vaccine remains a key objective if disease transmission
and severity is to be substantially reduced [3]. The most advanced
malaria vaccine in development, the protein-adjuvant vaccine
RTS,S/AS01 targeting the pre-erythrocytic stage of infection [4],
is currently in phase III clinical trials and has been shown to confer
partial protection over the 12 months following immunization
[5,6]. Whilst notable as the most efficacious malaria vaccine to
date there remains a considerable need to improve on its limited
clinical efficacy [7], either through modifications to the RTS,S
vaccine or by developing vaccine strategies that combine multiple
antigens or vaccine types [8].
Analysis of the immunological correlates of immunity induced
by the RTS,S vaccine in both phase IIa sporozoite challenge
studies [9,10] and a trial in Mozambique [11] provide evidence
that very high levels of antibodies to circumsporozoite protein (CS)
correlate with protection in humans [12]. However, this correla-
tion is relatively weak. It is unlikely that there is a component of
direct T cell mediated protection induced by the vaccine as the
magnitude of the CD4+ T cell response measured after
vaccination is modest (approximately 150 SFU /million PBMCs
on ELIspot) and no CD8+ T cells are induced [13].
Increasing data from animal models, fieldwork and inoculation
of volunteers with irradiated sporozoites support an important role
for CD8+ T cells in mediating pre-erythrocytic immunity, even in
the absence of antibodies [14]. Whilst pre-clinical studies
demonstrate a clear correlation between CD8+ T cells and
protection [15–19], clinical vaccine studies have been hampered
by the limited ability of existing subunit vaccine strategies, namely
adjuvanted protein constructs, to induce high enough numbers of
antigen specific CD8+ T cells to confer protection [20].
The Jenner Institute has been working to develop a T cell
inducing pre-erythrocytic P. falciparum malaria vaccine using the
sporozoite and liver stage antigen ME-TRAP. This antigen
contains a fusion protein of multiple epitopes (ME; a string of 20
epitopes, mainly CD8+ T cell epitopes from pre-erythrocytic
antigens) and the P. falciparum pre-erythrocytic antigen, thrombos-
pondin-related adhesion protein (TRAP) [21,22].
Multiple vectors for this antigen have been clinically tested
including DNA, fowl pox (FP) and the orthopox virus modified
vaccinia virus Ankara (MVA) [23–34]. Whilst some of these
vaccines are capable of inducing partial protection following
controlled human malaria infection (CHMI) in malaria naive
volunteers [21], this did not translate into efficacy in field studies
[32,33] likely due to a substantial reduction in T cell immuno-
genicity observed in malaria exposed vaccinees compared to UK
volunteers [32].
Most recently, heterologous prime boost immunization with
chimpanzee adenovirus 63 (ChAd63) followed by MVA, both
expressing ME-TRAP, has been shown to be the most immuno-
genic vaccine regimen to date, inducing more than 2000 IFNc
producing T cells post MVA boost in malaria naı̈ve volunteers
[35]. This translated into significant clinical efficacy following
CHMI administered by mosquito bite with both sterile and partial
protection observed for multiple vaccinees in a phase IIa trial in
the UK in which strong CD8+ T cell responses were induced (Ewer
et al. submitted).
The safety, immunogenicity and efficacy of malaria vaccines
may be affected by the intensity and pattern of local malaria
transmission which determine pre-existing natural immunity to
malaria and the potential natural ‘boosting’ of the vaccine induced
immune responses [29]. It is therefore useful to assess the safety
and immunogenicity of candidate vaccines in malaria exposed
adults prior to age de-escalation and administration to children
and infants, the target population. Here we present the safety and
immunogenicity results of two Phase Ib clinical trials of ChAd63-
MVA ME-TRAP in malaria exposed male adult volunteers, under
taken at two sites with similar malaria transmission patterns in
West and East Africa. Both studies included a dose escalation of
ChAd63 ME-TRAP and one site (Kenya) compared the safety and
immunogenicity of MVA ME-TRAP administered by intramus-
cular and intradermal routes.
Methods
The protocols for these trials and supporting CONSORT
checklist are available as supporting information; see Protocol S1,
Protocol S2 and Checklist S1.
Objective
The objective of the studies was to assess the safety and
immunogenicity of ChAd63 ME-TRAP and MVA ME-TRAP
administered in a heterologous prime boost regimen to healthy
malaria-exposed adults.
Study settings
The first trial (Trial A) was conducted at the Medical Research
Council (MRC) Unit field site located within Sukuta Health
Centre in Kombo North district of The Gambia, West Africa.
Sukuta village has an estimated population of 17,000 (2003
census). The climate is typical of sub-Saharan Africa with a long
dry season lasting from December–June followed by a relatively
short rainy season from July–November when the majority of P.
falciparum malaria transmission occurs [36].
The second trial (Trial B) was conducted in Vipingo, Kilifi
County, Kenya, East Africa. Participants were recruited from the
Rea Vipingo Sisal Plantation Estates in Kilifi which has over 1000
employees and a land area of 3,950 hectares. In Kilifi, there are
two seasons of high transmission of P. falciparum malaria coinciding
with the long monsoon rains (April to June) and the short rains
(October to December) [37].
Recent studies have reported a decline in malaria transmission
in both sites [38,39] but a surge was recorded during the period of
vaccinations in the Sukuta site (M. Afolabi personal communication).
Participants
Healthy males aged 18–50 years were invited to participate in
the studies. There was no selection of participants on the basis of
pre-existing neutralizing antibodies (NAb) to the ChAd63 vector
prior to enrolment. Volunteers were considered eligible if they
were consenting adult males aged 18–50 years in good health who
were likely to remain resident in the study area for the study
duration. Exclusion criteria included any evidence of any acute or
chronic illness or hematological, renal or hepatic pathology.
Specific exclusion criteria included; prior receipt of an investiga-
tional malaria vaccine, recent or planned use of any investigational
drug, vaccine, immunoglobulin or any blood product, confirmed
or suspected immunodeficiency, history of surgical splenectomy,
concurrent participation in another clinical trial or within 3
months of this study (see Protocol S1 (Trial A: The Gambia),
Protocol S2 (Trial B: Kenya) for the full list of inclusion and
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exclusion criteria). Blood positivity for P. falciparum at screening
was not an exclusion criterion.
Study Design
We conducted two Phase Ib open-label, dose-escalation malaria
vaccine trials (Figure 1). Both clinical trials evaluated low (161010
vp) and high dose (561010 vp) ChAd63 ME-TRAP. Trial B also
compared intramuscular and intradermal routes of administration
of 26108 pfu MVA ME-TRAP. The same lot of each vaccine was
used in both trials. The trials were conducted independently
however the same Data and Safety Monitoring Board (DSMB)
was used for each trial. The clinical trial protocols and supporting
CONSORT checklist are available as Supplementary Informa-
tion; see Protocol S1 (Trial A: The Gambia), Protocol S2 (Trial B:
Kenya), and Checklist S1.
In Trial A, eligible participants were allocated to receive either
ChAd63 ME-TRAP 161010 viral particles (vp) (group 1; n = 6) or
ChAd63 ME-TRAP 561010 vp (group 2; n = 10) administered
intramuscularly in the deltoid. All participants were subsequently
vaccinated in the opposite arm 56 days later with 26108 plaque
forming units (pfu) MVA ME-TRAP administered intramuscular-
ly. The first participant in group 1 to receive ChAd63 ME-TRAP
161010 vp was vaccinated in isolation. 48 hours later, two further
participants were enrolled in group 1. Prior to dose escalation of
ChAd63 ME-TRAP from 161010 vp to 561010 vp, safety data
from group 1 up to 14 days post ChAd63 ME-TRAP was
reviewed by the DSMB. There was a protocol-required interval of
at least 14 days between immunization of groups 1 and 2. Details
of clinical follow-up and safety monitoring are given in Protocol S1
and S2.
In Trial B, eligible participants were allocated to receive either
ChAd63 ME-TRAP 161010 viral particles (vp) (group 1; n = 10) or
ChAd63 ME-TRAP 561010 vp (group 2; n = 20) administered
intramuscularly in the deltoid. All participants were subsequently
vaccinated in the opposite arm 56 days later with 26108 plaque
forming units (pfu) MVA ME-TRAP. Participants in each group
were randomised 1:1 to receive MVA ME-TRAP administered
intramuscularly (IM) or intradermally (ID). The first 3 participants
in group 1 were vaccinated with ChAd63 ME-TRAP 161010 vp 7
days ahead of the remaining 7 participants in this group. There
was an 8 day interval between enrolment of group 1 and group 2.
Details of clinical follow-up and safety monitoring are given in
Protocol S1 and S2.
For both trials, a time window ranging between 1 and 28 days
depending on the visit was allowed for vaccination and follow-up
visits. Throughout the paper, study day refers to the nominal time
point for a group and not the actual day of sampling.
Randomisation in Trial B
30 participants were systematically allocated to receive either
161010 vp ChAd63 ME - TRAP or 561010 vp dose ChAd63 ME
in a ratio of 1:2. 8 weeks later participants were randomised 1:1 to
receive 26108 pfu MVA ME-TRAP administered intramuscularly
(IM) or intradermally (ID). The randomization sequence was
generated by an independent statistician using STATA pro-
gramme. Group allocations were kept in sealed opaque envelopes
Figure 1. Clinical Trial Designs. Trial A = Phase Ib clinical trial in The Gambia, West Africa. Trial B = Phase Ib clinical trial in Kilifi, Kenya, East Africa.
IM = intramuscular administration. ID = intradermal administration. In Trial A, 10 volunteers were excluded following screening for the following
reasons: severe thrombocytopenia, severe proteinuria, spastic deformity of arm and withdrawal of consent (seven individuals). In Trial B, 14
volunteers were excluded following screening for the following reasons: hypertension (two individuals), positive serology for HIV (two individuals),
positive Hepatitis B surface antigen (four individuals), participation in a previous malaria vaccine trial (2 individuals), peptic ulcer disease, allergic
disease, recruitment complete (one participant).
doi:10.1371/journal.pone.0057726.g001
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stored in a locked cabinet by the study coordinator who gave them
to the research nurses on day of vaccination. Participants and
clinical study staff were un-blinded to group allocation, however,
field workers were blinded to group allocation.
Sample size
These were observational and descriptive studies to assess the
safety and immunogenicity of ChAd63 ME-TRAP and MVA ME-
TRAP in malaria exposed adults. The sample sizes were chosen to
allow estimation of the magnitude of the primary outcome
measures, especially of serious adverse events (AEs) rather than
assessment of statistically significant differences between groups.
Ethical & Regulatory Approval
The clinical trial protocols and associated documents were
approved by Gambia Government/MRC Joint Ethics Committee
for Trial A and The Kenya Medical Research Institute National
Ethics Review Committee for Trial B. Documents for both clinical
trials were reviewed and approved by the Oxford Tropical
Research Ethics Committee (OXTREC). Regulatory approval
was given by the Medicines Board of The Gambia for Trial A and
The Pharmacy and Poisons Board of Kenya for Trial B. All
participants gave documented informed consent prior to any study
procedure being undertaken. The study was conducted according
to the principles of the Declaration of Helsinki (2008) and the
International Conference on Harmonization (ICH) Good Clinical
Practice (GCP) guidelines. An independent DSMB and local safety
monitors provided safety oversight and GCP compliance was
independently monitored by an external organization at both trial
sites (Appledown Clinical Research Ltd, Great Missenden, UK).
ChAd63 ME-TRAP and MVA ME-TRAP Vaccines
Generation of the recombinant vectors has been previously
described [40,41]. Vaccines were manufactured under Good
Manufacturing Practice (GMP) conditions by the Clinical
Biomanufacturing Facility, University of Oxford (ChAd63 ME-
TRAP) and IDT Biologika GmbH, Dessau, Germany (MVA ME-
TRAP). Briefly, ChAd63 ME-TRAP was grown in suspension
HEK293 cells and purified by caesium chloride density-gradient
centrifugation. MVA ME-TRAP was generated in chicken
embryo fibroblasts (CEFs) and purified by sucrose density-gradient
centrifugation. Each vaccine lot underwent comprehensive quality
control analysis to ensure that the purity, identity and integrity of
the virus met pre-defined specifications. Vaccine lots were stored
at the clinical site in a 270uC freezer and vaccines were
temperature monitored when moved.
The antigen ME-TRAP contains a fusion protein of multiple
epitopes (ME) and the P. falciparum pre-erythrocytic thrombos-
pondin-related adhesion protein (TRAP). The ‘ME’ is a string of
20 epitopes, mainly CD8 T cell epitopes from P. falciparum pre-
erythrocytic antigens, fused to the thrombospondin-related adhe-
sion protein. The individual cytotoxic T lymphocyte (CTL)
epitopes which constitute the ‘multiple epitope’ part of ME-TRAP
represent six potentially protective target antigens and are
included to try to broaden the immune response rate in the
vaccinated population. The ME string is fused to the entire
sequence of the T9/96 strain of P. falciparum TRAP and the ME-
TRAP hybrid is a 2398 base-pair insert which encodes for a single
polypeptide of 789 amino acids [21].
Safety
In each trial participants were observed for 1 hour post each
immunization. Following each immunization participants in both
trials were reviewed at home by a trained field worker and findings
recorded on standardised case report forms. Local and systemic
vaccine reactogenicity was evaluated and graded for severity,
outcome and association to vaccination as per the criteria outlined
in Tables 1, 2, 3, 4, 5. Local solicited reactions were; pain,
discoloration, swelling, warmth, pruritus, scaling or blistering at
the injection site. Systemic solicited symptoms were; fever (axillary
temperature.37.5uC), feverishness, malaise, arthralgia, headache,
myalgia and nausea or vomiting. Unsolicited symptoms that
occurred within 30 days of each immunization were assessed,
recorded and their relationship to the immunization determined.
Serious adverse events (SAEs) were assessed throughout the study
period. First responseH Rapid Diagnostic kits (Trial A) or blood
film microscopy (Trial B) [42] were performed for diagnostic
purposes whenever participants presented with symptoms sugges-
tive of malaria at each trial site. In Trial A blood was sampled at
all clinic visits post vaccination (days 14, 56, 63, 90 and 300 post
ChAd63 ME-TRAP) and full blood count, creatinine and alanine
aminotransferase (ALT) measured. In Trial B blood was sampled
at all clinic visits post vaccination (days 14, 56, 63, 91 and 308 post
ChAd63 ME-TRAP) and full blood count, creatinine and ALT
measured.
Peripheral Blood Mononuclear Cell (PBMC) and Serum
Preparation
Blood samples were collected into lithium or sodium heparin-
treated vacutainer blood collection tubes (Becton Dickinson, UK).
PBMC were isolated and used within 6 hours in fresh assays as
previously described [43]. Excess cells were frozen in foetal calf
serum (FCS) containing 10% dimethyl sulfoxide (DMSO) and
stored in liquid nitrogen. For serum preparation, untreated blood
samples were stored at 4uC and then the clotted blood was
centrifuged for 5 min (1000 xg). Serum was stored at 280uC.
Peptides for T cell Assays
Peptides were purchased from NEO Peptide (Cambridge, MA,
USA). The peptides, 20 amino acids (aa) in length and overlapping
by 10 aa covered the entire ME-TRAP insert present in the viral
vectored vaccines. Peptides were also synthesised for the sequence
Table 1. Assessment of Severity of Local AEs. Discoloration.
Grade Diameter (mm)
0 0
1 ,50
2 50–100
3 .100
doi:10.1371/journal.pone.0057726.t001
Table 2. Assessment of Severity of Local AEs. Swelling.
Grade Diameter (mm)
0 0
1 ,20
2 20–50
3 .50
doi:10.1371/journal.pone.0057726.t002
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of TRAP from the 3D7 strain. Peptides were reconstituted in
100% DMSO at 50–200 mg/mL and combined into various pools
for ELISPOT and flow cytometry assays. Peptides are listed in
Table S1.
Ex-vivo interferon-c (IFN-c) ELISPOT
The kinetics and magnitude of the T cell response to ME-TRAP
were assessed over time by ex-vivo IFN-c ELISPOT assays
performed on blood samples taken at each clinic review (days
14, 56, 63, 90 and 300 post ChAd63 ME-TRAP in Trial A and
days 14, 56, 63, 91 and 308 post ChAd63 ME-TRAP in Trial B).
Ex-vivo IFN-c ELISPOT assays were performed with an 18–
20 hour stimulation of PBMC with peptides pools containing up to
10 peptides per pool, including peptides representing the T9/96
and 3D7 strains. Fresh PBMC were used in all ELISPOT assays
using a previously described protocol, except that 50 mL/well ME-
TRAP peptide pools (final concentration of each peptide 10 mg/
mL) were added to duplicate wells, 50 mL/well R10 and DMSO
control were added to negative un-stimulated wells, and 50 mL/
well Staphylococcal enterotoxin B (SEB) (final concentration
0.02 mg/mL) plus phytohemagglutinin (PHA) (final concentration
10 mg/mL) was added to positive control wells. Spots were
counted using an ELISPOT counter (Autoimmun Diagnostika
(AID), Germany). Results are expressed as the mean of the
duplicate IFN-c spot-forming units (SFU) per million PBMC.
Background responses in un-stimulated control wells were almost
always less than 20 spots, and were subtracted from those
measured in peptide-stimulated wells. Responses are shown as the
summed response to all the ME-TRAP (T9/96) peptide pools
(unless otherwise stated).
Statistical Analysis
Data were analyzed using GraphPad Prism version 5.03 for
Windows (GraphPad Software Inc., California, USA) and Stata
10.0 (Statacorp LP, Texas, USA). Geometric mean or median
responses for each group are described. Significance testing of
differences between two groups used the two-tailed Mann-
Whitney U test or Wilcoxon signed rank test as appropriate.
Correlations were analyzed using Spearman’s rank correlation co-
efficient (rs) for non-parametric data. Collated immunology data
was analysed by multivariate linear regression using log-trans-
formed ELISPOT results. A value of P,0.05 was considered
significant.
Results
Study Recruitment
Recruitment for Trial A took place in the Gambia between 19th
May 2010 and 9th June 2010. Sixteen healthy male adult
participants were enrolled, immunized and followed up
(Figure 1). The mean age of volunteers was 33.3 years (range
23–48 years). All participants were from the Mandinka ethnic
group. Vaccinations began in June 2010 and all follow-up visits
were completed by May 2011. With the exception of a participant
in group 2 who was lost to follow-up after review on Day 90, all
volunteers attended all visits as scheduled and completed the
study.
Recruitment for Trial B took place in Kenya between 10th June
2010 and 7th July 2010. Thirty healthy male adult participants
were enrolled, immunized and followed up (Figure 1). The mean
age of volunteers was 32.5 years (range 22–50). 47% of
participants were from the Mijikenda ethnic group, 27% were
Luos and the remaining 26% from other ethnic groups.
Vaccinations began in June 2010 and all follow-up visits were
completed by May 2011. All volunteers attended all visits as
scheduled and completed the study.
Safety and Reactogenicity
No unexpected AEs or SAEs occurred and no volunteers were
withdrawn due to AEs. AEs associated with ChAd63 ME-TRAP
AEs were all mild in intensity (Figure 2 & Table S2). No clear
difference in reactogenicity was noted between participants
receiving 161010 vp and 561010 vp ChAd63 ME-TRAP. All
AEs resolved without sequelae within 72 hours of immunization.
MVA ME-TRAP was more reactogenic than ChAd63 ME-TRAP
though still well tolerated with the majority of AEs mild in
intensity (Figure 3 & Table S2). Whilst systemic reactogenicity of
MVA ME-TRAP was unaffected by route of administration,
intradermal injection was associated with increased local reacto-
genicity (namely injection site swelling, warmth, discoloration,
Table 3. Assessment of Severity of Local AEs. Pain.
Grade Description
0 No pain at all
1 Painful to touch, no restriction in movement of arms, able to work, drive, carry heavy objects as normal
2 Painful when limb is moved (i.e. restriction in range of movement in arm, difficulty in carrying objects)
3 Severe pain at rest (i.e. unable to use arm due to pain.)
doi:10.1371/journal.pone.0057726.t003
Table 4. Assessment of Severity of Systemic AEs.
Scale Description Definition
0 Absence of the indicated symptom
1 Mild Awareness of a symptom but the symptom is easily tolerated
2 Moderate Discomfort enough to cause interference with usual activity
3 Severe Incapacitating; unable to perform usual activities; requires absenteeism or bed rest
doi:10.1371/journal.pone.0057726.t004
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blistering and pain) compared to intramuscular administration. All
AEs resolved without sequelae. Local AEs post-MVA ME-TRAP
resolved between 1 to 15 days post immunization apart from one
case of swelling that lasted for 30 days occurring in an individual
who received MVA ME-TRAP intradermally (maximum 35 mm
of swelling gradually resolving over time, not associated with a
Table 5. Assessment of Relationship of AE to Immunization.
0 No Relationship No temporal relationship to study product and Alternate aetiology (clinical state, environmental or other interventions); and
Does not follow known pattern of response to study product
1 Possible Reasonable temporal relationship to study product; or Event not readily produced by clinical state, environmental or other
interventions; or Similar pattern of response to that seen with other vaccines
2 Probable Reasonable temporal relationship to study product; and Event not readily produced by clinical state, environment, or other
interventions or Known pattern of response seen with other vaccines
3 Definite Reasonable temporal relationship to study product; and Event not readily produced by clinical state, environment, or other
interventions; and Known pattern of response seen with other vaccines
doi:10.1371/journal.pone.0057726.t005
Figure 2. Local and systemic AEs deemed definitely, probably or possibly related to ChAd63 ME-TRAP. Only the highest intensity of
each AE per subject is listed. Data are combined for all AEs for all volunteers receiving the same vaccine at the stated dose. There were no
immunization related serious AEs. IM = intramuscular. (A) Local AEs post ChAd63 ME-TRAP. (B) Systemic AEs post ChAd63 ME-TRAP.
doi:10.1371/journal.pone.0057726.g002
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sterile abscess). Systemic AEs post-MVA ME-TRAP resolved
within 48 hours of immunization. Minor laboratory abnormalities
were seen post immunization. However, all were mild, clinically
insignificant and resolved fully (Table S3). In Trial A, two
volunteers were diagnosed and treated for P. falciparum malaria by
First responseH Rapid Diagnostic kits; one volunteer in group 1, 6
months post MVA ME-TRAP and another in group 2, 34 days
post MVA ME-TRAP. These volunteers demonstrated no unusual
features of the illness and were included in the final analyses.
Similarly, 2 volunteers in Trial B were diagnosed and treated for P.
falciparum malaria by blood film, one on day 17 and one on day
139 and were included in the final analyses. These volunteers
demonstrated no unusual features of the illness.
Immunogenicity
Heterologous prime boost with ChAd63-MVA ME-TRAP
induced high frequencies of antigen-specific IFNc-secreting T
cells in both trials as measured by ex-vivo IFNc ELISPOT. Peak
IFNc ELISPOT responses were detected 7 days post MVA ME-
TRAP when a positive response (defined as responses above the
lower limit of detection and at least double the response measured
at Day 0) was detected in 90% and 100% of recipients in Trial A
and Trial B respectively (Table 6 & Figure 4A). Responses were
well maintained post immunization and detectable in 88% of all
vaccinees 9 months after the final immunization (median
116 SFC/106 PBMC, 95% CI 133, 268).
In Trial A there was no statistically significant difference in peak
IFNc ELISPOT response between individuals receiving 161010
Figure 3. Local and systemic AEs deemed definitely, probably or possibly related to MVA ME-TRAP. Only the highest intensity of each
AE per subject is listed. Data are combined for all AEs for all volunteers receiving the same vaccine at the stated dose. There were no immunization
related serious AEs. IM = intramuscular. ID = Intradermal. (A) Local AEs post MVA ME-TRAP. (B) Systemic AEs post MVA ME-TRAP.
doi:10.1371/journal.pone.0057726.g003
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Figure 4. IFN-c ELISPOT responses to ChAd63-MVA ME-TRAP. (A) Time course of IFN-c ELISPOT responses to ChAd63-MVA ME-TRAP. Lines
show median immune response to high dose (solid line) and lower dose (dashed line) of ChAd63 ME-TRAP in Trial A (grey line) and Trial B (black line).
For Trial B medians are for groups with MVA given IM and ID combined. (B) Peak immune response (day 63–7 days post MVA vaccination) to ChAd63
and MVA ME-TRAP stratified by route of administration of MVA, dose of ChAd63 and trial site. Bar represents geometric mean. Circles represent MVA
given IM, squares represent MVA given ID. Closed symbols represent 161010 vp ChAd63 and open symbols 561010 vp ChAd63.
doi:10.1371/journal.pone.0057726.g004
Table 6. Comparison of IFN-c ELISPOT data between African & UK volunteers receiving ChAd63-MVA at peak of vaccine induced
immune response (7 days post immunization with MVA ME-TRAP 26108 pfu).
Trial Site Kenya Kenya Kenya Kenya Gambia Gambia Oxford Oxford Oxford
Route of Admin IM ID IM ID IM IM ID IM ID
MVA ME-TRAP
Dose ChAd63 ME-TRAP
vp
161010 161010 561010 561010 161010 561010 161010 561010 561010
(All IM)
Number Participants 5 5 10 10 6 9 4 4 4
Median 426 906 1334 1699 266 1558 2465 1410 1031
IQR 208–945 529–1704 712–2382 1101–2410 129–909 333–2443 910–3138 932–1571 319–1707
Values are SFC per million PBMC for summated peptide pools spanning the length of the ME-TRAP insert tested in duplicate with response to negative (medium)
control wells subtracted. IM = intramuscular administration. ID = intradermal administration. Vp = virus particles.
doi:10.1371/journal.pone.0057726.t006
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vp ChAd63 ME-TRAP (median 266 SFC/106 PBMC, 95% CI -
208, 1310) and individuals receiving 561010 vp ChAd63 ME-
TRAP (1558 SFC/106 PBMC, 95% CI 550, 2179) (p = 0.11;
Mann Whitney U, 2 tailed test). In contrast in Trial B, the median
peak IFNc ELISPOT response elicited in individuals receiving
561010 vp ChAd63 (1536 SFC/106 PBMC (95% CI 1230, 2355)
was significantly greater than the peak response in individuals
receiving 161010 vp ChAd63 ME-TRAP (590 SFC/106 PBMC,
95% CI 399, 1314, p = 0.011 2 tailed Mann Whitney test).
In Trial B there was no significant difference in peak immune
response between volunteers receiving MVA administered intra-
muscularly or intradermally for either dose of ChAd63 ME-TRAP
(ChAd63 ME-TRAP 161010 vp p = 0.22; ChAd63 ME-TRAP
561010 vp p = 0.62, 2-tailed Mann Whitney test) (Figure 4B and
Table 6).
ELISPOT data was combined from both trials and analysed
using a multivariate linear regression model. Data was stratified by
dose of ChAd63 ME-TRAP and trial site. Only dose of ChAd63
ME-TRAP had a significant effect with a 2.3 (95% CI 1.4–3.8)
fold increase in mean ELISPOT response in the individuals
receiving 561010 vp. Of note, route of administration and trial
site did not have significant effects on outcome (0.86 fold increase
[95% CI 0.4–1.4], p = 0.4 for IM versus ID, 1.66fold increase
[95% CI 0.9–3.0], p = 0.1 for Kenya versus The Gambia).
Discussion
In these two Phase Ib trials we have shown in healthy, malaria-
exposed adult volunteers that a recombinant ChAd63-MVA
heterologous prime-boost immunization regimen encoding ME-
TRAP is safe as well as very immunogenic for T-cell induction.
ChAd63 ME-TRAP demonstrated an excellent safety profile,
inducing only a small number of AEs, all of which were mild in
intensity. ChAd63 ME-TRAP had a similar reactogenicity profile
in our malaria exposed population to that seen in UK volunteers
who received comparable doses of ChAd63 ME-TRAP [35]. No
clear increase in reactogenicity was noted with the dose escalation
of ChAd63, consistent with data from UK volunteers [35]. These
findings add to the growing evidence that ChAd63 is a safe vector
for clinical use [35,43,44].
The safety and immunogenicity of intradermally administered
MVA ME-TRAP at doses of up to 1.56108 pfu MVA ME-TRAP
have previously been assessed in malaria exposed adults [28–30].
Our data, presented here show that increasing the dose of MVA
ME-TRAP administered intradermally to malaria exposed adults
to 26108 pfu is associated with an increase in frequency but not
severity of local AEs, causing relatively short-lived injection site
pain, discoloration, warmth and swelling (with the exception of
one case of moderate injection site swelling lasting 30 days). The
increased dose of MVA ME-TRAP did not however translate into
an increase in systemic reactogenicity. MVA ME-TRAP admin-
istered intramuscularly in our subjects was associated with
considerably fewer local AEs than intradermal administration;
however, short-lived injection site pain was still reported by 97%
of volunteers. This finding was also seen in UK volunteers [35].
In agreement with data from previous clinical studies of
ChAd63 vectored vaccines,[35,43] there was a significant increase
in IFNc responses post MVA boost in groups receiving the higher
dose of ChAd63 ME-TRAP (561010 vp). Of note, there was no
statistically significant difference in peak immune responses
between individuals in Trial B who received MVA ME-TRAP
administered intradermally or intramuscularly. Given this finding
and the increased frequency of local AEs associated with
intradermal administration, future studies in adults will use
26108 pfu MVA ME-TRAP administered intramuscularly.
Whilst a previous study of vectored malaria vaccines observed a
reduction in T-cell immunogenicity in malaria exposed popula-
tions compared to UK volunteers [32], IFNc responses in our
volunteers receiving 561010 vp ChAd63 ME-TRAP were
comparable with Phase Ia data (Table 6) [35]. Further analysis
will assess the cellular composition of T-cell responses to assess and
quantify mono-functional gamma-interferon-secreting CD8+ T
cells as potential markers of vaccine efficacy (Ewer et al. submitted).
However, importantly the vaccine-induced T cell responses
reported here appear to be the most potent reported to date in
Africa for any vaccine type. Responses exceeding 1000 SFU /
million PBMCs are very difficult to induce with any vaccination
strategy and the levels attained here in this first study of ChAd63-
MVA in Africa are therefore encouraging for more widespread use
of these vaccine vectors.
Concerns have been raised that pre-existing anti-vector
immunity could limit the immunogenicity or compromise safety
of adenoviral vectored vaccines in exposed populations[45,46].
Low prevalence of serum neutralising antibodies to ChAd63 in the
target population [46] and the proven potency of ChAd63 in pre-
clinical and clinical studies [35,43,44,47], including those studied
here, make this a promising vector. Further analysis will assess the
relationship between baseline anti-ChAd63 antibodies and immu-
nogenicity.
Chimpanzee adenoviruses were first used as a vaccine in
humans in 2007 [35] and are now in clinical development for HIV
(Hanke et al unpublished), Hepatitis C [47], pandemic influenza
(Gilbert et al. unpublished) as well as for liver-stage and blood-stage
malaria [43,48]. All of these vaccines will have major target
populations in Africa and these initial safety and immunogenicity
data from African vaccinees are therefore of interest for many
disease areas.
Future Phase Ib studies will now assess the safety and
immunogenicity of ChAd63-MVA ME-TRAP in children and
infants. If these data are favourable, field efficacy studies will be
undertaken in infants to assess whether strong cellular immunity
against ME-TRAP can translate into significant efficacy against
naturally acquired P. falciparum infection and disease in the field.
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Table S1 TRAP T9/96 and 3D7 peptide sequences and
peptide pools. The sequences in bold represent the 3D7 strain
sequences that differ from the T9/96 strain. When no sequence is
present for the 3D7 strain, it means that both the 3D7 and T9/96
sequences are identical and the T9/96 peptide has been used in
the 3D7 pool.
(PDF)
Table S2 Local and systemic AEs deemed definitely,
probably or possibly related to ChAd63 ME-TRAP or
MVA ME-TRAP. Only the highest intensity of each AE per
subject is listed. Data are combined for all AEs for all volunteers
receiving the same vaccine at the stated dose. Number = number
of volunteers experiencing named AE. % = percentage of
immunised volunteers experiencing named AE. There were no
immunization related serious AEs. IM = intramuscular admin-
istration. ID = intradermal administration.
(PDF)
Table S3 Laboratory abnormalities post immunization
deemed definitely, probably or possibly related to
ChAd63 ME-TRAP or MVA ME-TRAP. All were mild,
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deemed possibly related to vaccination and resolved fully with no
long term sequelae. None of the laboratory abnormalities were
deemed clinically significant. All laboratory abnormalities resolved
by time of next venepuncture* (duration of abnormality is
therefore likely to be overestimated, as the abnormality may have
resolved prior to retesting). ALT = alanine aminotransferase.
(PDF)
Checklist S1 CONSORT Checklist.
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Protocol S1 Clinical trial protocol for Trial A.
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Protocol S2 Clinical trial protocol for Trial B.
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